Okay, hereS a revised and fact-checked version of the provided text, addressing potential inaccuracies and clarifying information based on current understanding of VNS for treatment-resistant depression. I’ve focused on ensuring the definitions and claims align with established medical knowledge. I’ve also added some context where appropriate.
Please note: I am an AI and cannot provide medical advice. This is a revised text based on information available as of today, January 16, 2024. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Vagus Nerve Stimulation Shows Sustained Benefit in Highly Treatment-Resistant Depression
This study investigates the long-term effects of Vagus Nerve Stimulation (VNS) as an adjunct to Treatment As Usual (TAU) in individuals with highly treatment-resistant depression (TRD).
Methods & Definitions
The study utilized the Work Productivity and Activity Disorders Questionnaire to assess functional improvements. A clinically meaningful improvement (Mo) was defined as a reduction of two points or more on this questionnaire.
All measures (symptoms, function, and quality of life – QdV) were combined into a single composite measure. A composite score of 0.3 was based on the number of domains demonstrating a Mo. A score of 0 indicated no meaningful benefit (N.-B.), 1 indicated a Mo, and scores of 2 or 3 indicated significant benefit (SB). Outcome measures were assessed at 12, 18, and 24 months after randomization.
Sustainability of benefit was resolute by the proportion of participants achieving at least Mo at 12 months who maintained or improved to at least that level at 18 and 24 months. Loss of benefit was defined as a shift from Mo or SB at 12 months to N.-B. at later time points. Relapse was defined as achieving SB at 12 months but reverting to N.-B. at subsequent assessments. The study also evaluated improvements in patients initially categorized as N.-B. at 12 months.
Study Population & Results
The study included 214 participants with an average age of 55.2 years. the majority were women (68%) and unemployed (72%). Participants had a long history of depressive illness (averaging 52.6% of their life), had previously failed multiple antidepressant and other interventions, and presented with significant functional impairment and poor quality of life (QdV).
At 12 months, 80% of participants achieved at least Mo on the composite measure. This proportion remained high at 18 months (83.6%) and 24 months (82.4%).
Among those in remission (defined as achieving at least Mo) at 12 months, approximately 59-66% maintained remission at 18 months, and 48-70% remained in remission at 24 months. Loss of benefit occurred in approximately 17% of participants at 18 months and 19% at 24 months.
The relapse rate was 6.7% at 18 months and 7.8% at 24 months. Importantly, a substantial proportion of participants initially categorized as N.-B. at 12 months experienced a benefit at later time points, with approximately one-third achieving at least Mo by 18 months and nearly 38% by 24 months.
conclusion
The results demonstrate that VNS, when used as an adjunct to TAU, provides sustained benefit for a significant proportion of individuals with highly treatment-resistant depression. Approximately 80% of participants who achieved at least Mo at 12 months maintained that level of improvement over the following 12 months. Moreover,a notable percentage of those who did not initially respond to VNS experienced a benefit over time. The low rates of loss of benefit and relapse, coupled with the emergence of benefit in previously non-